A single name is carrying the tape. META +5.7% reprices its AI infrastructure story after a SemiAnalysis report and a BofA note reframed its capacity build as far more capital-efficient than the Street had modeled. Semis follow — NVDA +3.6%, STX +3.6% — while the rotation cuts the other way in high-multiple software (CRWD −5.6%, PANW −4.2%) and a sharp biotech unwind (MRNA −11.0%). Energy lags as crude fades. A quiet VIX 15.4 and firm 10Y near 4.56% frame a bid but two-sided tape into CPI next Tuesday.

SPX +0.20% trades near 7,559 at a fresh high, but the index-level move understates the churn beneath it. This is a narrow, top-heavy tape: META alone accounts for an outsized share of the gain, with the rest of the megacap complex mixed. The Nasdaq +0.19% and Dow +0.12% are both marginally green, essentially flat once the AI-infrastructure winners are stripped out. The clear tell is RTY −0.72% — small caps are diverging lower rather than confirming, a sign the strength is concentrated in a handful of mega-cap AI names rather than broadening.

The driver is a re-rating of Meta's capital spending. A SemiAnalysis report and a fresh Bank of America note (Justin Post, $835 target) reframed Meta's AI capacity build as tracking closer to ~$22B per gigawatt versus prior Street estimates near $45B — flipping the long-standing bear case that its capex would incinerate cash without a return. The read-through pulled the AI-infrastructure and memory complex higher. The mirror image is a rotation out of high-multiple software and cybersecurity and a pronounced unwind in biotech, where money is coming out of names that had run hard. The backdrop stays firm on rates: the 10Y sits near 4.56% and crude is fading, keeping energy and rate-sensitives on the back foot.

VIX 15.37 (−3.0%) grinds to the low-15s as vol sellers press into the index strength. That is a calm surface against a firm rate backdrop and a still-hot single-stock tape underneath — the kind of complacent setup where a firm CPI print next Tuesday could re-price vol quickly.

Communications screens slightly negative on average (−0.2%, 15 advancers vs 25 decliners) but only because META +5.7% is doing all the lifting while the rest of the group is heavy: NFLX −3.6%, CHTR −3.4% and PANW −4.2% weigh. Meta's move is the whole market's story today — the AI-capex efficiency re-rating (see below) — and it dragged AI-infrastructure read-throughs higher even as the broad group lagged.

Technology is red on average (−0.4%) despite the AI-infrastructure bid, a split tape. The strength is in semis and hardware — NVDA +3.6%, STX +3.6% — while high-multiple software and cybersecurity are the funding source for the rotation: CRWD −5.6%, FTNT −3.7%, DDOG −3.8% and AKAM −2.8% all lower. There is no fresh single-name catalyst in the software leaders; this is money rotating out of expensive application/security names and into the infrastructure winners.

Consumer Non-cyclical is roughly flat at the sector level but hides the day's sharpest move: MRNA −11.0% leads a broad biotech unwind, with GILD −3.6% also heavy. Energy is the weakest group at −1.1% (3 advancers vs 19 decliners) as crude fades, with EQT −4.3% and EXE −4.1% the laggards. Basic Materials (+1.0%) and Consumer Cyclical (+0.9%, NKE +3.6%) are quietly the broadest advancers.

META +5.7%  Meta is the market today. The catalyst is a re-rating of its AI capital spending: a SemiAnalysis report gave Zuckerberg's rebuilt AI organization high marks, and — more materially for the stock — a Reuters-reported internal memo plus a BofA note argued Meta is building compute at roughly $22B per gigawatt versus the Street's prior ~$45B estimate. BofA's Justin Post reiterated Buy with an $835 target; Wolfe framed ~20% EPS upside per gigawatt monetized. Layered on top are the reported "Meta Compute" cloud unit (selling excess AI capacity, AWS/CoreWeave-style) and the in-house Iris chip entering production in September, though BofA flags Iris as a 2027-plus cost story, not a 2026 driver. Net: the move addresses the biggest bear overhang — that the capex would burn cash without ROI — which is why a single name can re-rate the whole AI-infrastructure complex. Q2 earnings 7/29 is the next hard catalyst.

MRNA −11.0%  Moderna leads a broad biotech unwind, with ImmunityBio and Sarepta also down ~8% in sympathy. There is no negative company catalyst — recent news has actually been constructive (EU combo-vaccine approval, an August 5 flu-vaccine PDUFA date, RBC lifting its target to $45). The move is profit-taking after a roughly 170% YTD run in a high-beta, pre-profit name: money is rotating out of speculative biotech and holding still in defensive large-cap pharma (LLY −1.6%, JNJ ~flat). The tell is whether the XBI stabilizes into the close or the rotation accelerates; the August 5 PDUFA is the next hard-dated catalyst for the name.

CRWD −5.6%  CrowdStrike leads high-multiple software and cybersecurity lower alongside PANW −4.2%, FTNT −3.7% and DDOG −3.8%. Again, no fresh single-name catalyst — analyst targets have generally been rising into the recent split. This is the funding side of today's rotation: capital moving out of expensive, priced-for-perfection software (CRWD trades north of 150x forward) and into the AI-infrastructure and memory winners that the Meta re-rating put back in favor. A day-to-day flow story, not a change in the demand backdrop.

The rates picture is the quiet counterweight to the equity bid. The 2s10s curve sits near 36bp with the 10Y around 4.56% — a firm backdrop that keeps financing conditions tight even as the index prints highs, and helps explain why rate-sensitive small caps (RTY −0.7%) are diverging lower. WTI −1.2% and nat gas −3.4% are the sharpest commodity moves, and crude's fade is the direct read-through to Energy's −1.1% underperformance. A modestly softer DXY and a slightly heavy gold near records round out a benign cross-asset picture. The setup is an index rally the bond market isn't endorsing — worth respecting into next week's CPI.